Sofosbuvir for Hepatitis C Genotype 2 or 3 in Patients without Treatment Options
Ira M. Jacobson(Cornell University), David R. Nelson(Harvard University Press), Eugene R. Schiff(University of Miami), Michael Bennett(Associates Research), Stuart C. Gordon(United States Department of Veterans Affairs), William T. Symonds(Gilead Sciences (United States)), Jordan J. Feld(University Health Network), M. Rodríguez‐Torres(Puerto Rico Community Foundation), Mark Sulkowski(Johns Hopkins University), Gregory T. Everson(ColdQuanta, Inc., DBA Infleqtion (United States)), Di An(Gilead Sciences (United States)), John G. McHutchison(Gilead Sciences (United States)), Eric M. Yoshida(Vancouver General Hospital), Eric Lawitz(The University of Texas at San Antonio Health Science Center), G. Mani Subramanian(Pacific Biosciences (United States)), Kris V. Kowdley(Liver Institute Northwest), M. Lin(Gilead Sciences (United States)), M. Tarek Al-Assi(Texas Digestive Disease Consultants), Diana M. Brainard(Gilead Sciences (United States)), Stephen Pianko(Monash Medical Centre), Mitchell L. Shiffman(Bon Secours Health System), John McNally(Gilead Sciences (United States)), Keyur Patel(Duke University)
Cited by 1,082
Related Papers
Development of a simple noninvasive index to predict significant fibrosis in patients with HIV/HCV coinfection†‡
|Hepatology|2006|4.8k
Pioglitazone, Vitamin E, or Placebo for Nonalcoholic Steatohepatitis
|New England Journal of Medicine|2010|3.3k
A multisociety Delphi consensus statement on new fatty liver disease nomenclature
|Hepatology|2023|2.9k
A multisociety Delphi consensus statement on new fatty liver disease nomenclature
|Journal of Hepatology|2023|2.7k